In tackling high drug prices, FTC shows partisan split

Combating unreasonable, unilateral drug price hikes is a big talking point on the presidential campaign trail. But when lawmakers asked the Federal Trade Commission about whether it could help, the commissioners...

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:
Email: customerservices@mlex.com

FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch
Current Issue: 1005
Next Issue: May 25, 2021

Vote Now!

Our journalists are competing in the 2021 Antitrust Writing Awards.

Winners will be announced at a virtual ceremony on June 30.

Click below to vote now!

Breaking Down Barriers: Recruiting and Promoting Black Antitrust Lawyers

Microsoft, Northern Securities Cases Paved Way for Google Antitrust Showdown